a Significant increases in BDI scores were observed during months 2–3 of leuprolide treatment compared with baseline scores (F=3.5, df=2, 154, p=0.03; Bonferroni-corrected t=2.6, df=155, p<0.03), but not when compared with month 1 of leuprolide treatment. One of the 72 women (1.3%) had a BDI score ≥18 after 6 weeks of leuprolide treatment; the symptoms did not persist for 2 consecutive weeks. Four women overall (5.6%) had BDI scores ≥10, and in only one woman did symptoms persist for 2 consecutive weeks (i.e., two visits).